• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    98.13 +0.31 (+0.32%)
    Streaming Delayed Price Updated: 10:29 AM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 162,845
    Open 98.65
    Bid (Size) 98.01 (300)
    Ask (Size) 98.18 (100)
    Prev. Close 97.82
    Today's Range 96.58 - 98.70
    52wk Range 56.13 - 112.29
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
    Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors. 
    Via Chartmill

    Performance

    YTD
    -3.2%
    -3.2%
    1 Month
    +8.1%
    +8.1%
    3 Month
    -4.4%
    -4.4%
    6 Month
    +13.9%
    +13.9%
    1 Year
    +72.8%
    +72.8%

    More News

    Read More
    News headline image
    Incyte to Report First Quarter Financial Results
    From Incyte
    Via Business Wire
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
    From Adagene Inc.
    Via GlobeNewswire
    Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗
    Via Chartmill
    News headline image
    A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
    From Incyte
    Via Business Wire
    News headline image
    Incyte Announces Executive Leadership Appointments
    From Incyte
    Via Business Wire
    News headline image
    2 Growth Stocks with Explosive Upside and 1 We Avoid
    Via StockStory
    News headline image
    Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
    From Incyte
    Via Business Wire
    News headline image
    1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
    Via StockStory
    News headline image
    2 Value Stocks to Consider Right Now and 1 We Ignore
    Via StockStory
    News headline image
    Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
    Via StockStory
    Topics Stocks
    News headline image
    Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
    Via Stocktwits
    News headline image
    Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
    From Incyte
    Via Business Wire
    News headline image
    1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
    Via StockStory
    News headline image
    3 S&P 500 Stocks to Target This Week
    Via StockStory
    Topics Stocks
    News headline image
    Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    1 Unpopular Stock That Deserves a Second Chance and 2 We Question
    Via StockStory
    News headline image
    Registration Momentum Builds Across the Oncology Pipeline
    From USA News Group
    Via GlobeNewswire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
    Via StockStory
    Topics Earnings
    News headline image
    Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
    Via Finterra
    Topics Economy Intellectual Property

    Frequently Asked Questions

    Is Incyte Corporation - Common Stock publicly traded?
    Yes, Incyte Corporation - Common Stock is publicly traded.
    What exchange does Incyte Corporation - Common Stock trade on?
    Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Incyte Corporation - Common Stock?
    The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
    What is the current price of Incyte Corporation - Common Stock?
    The current price of Incyte Corporation - Common Stock is 98.13
    When was Incyte Corporation - Common Stock last traded?
    The last trade of Incyte Corporation - Common Stock was at 04/20/26 10:29 AM ET
    What is the market capitalization of Incyte Corporation - Common Stock?
    The market capitalization of Incyte Corporation - Common Stock is 21.83B
    How many shares of Incyte Corporation - Common Stock are outstanding?
    Incyte Corporation - Common Stock has 22B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.